NCT04336410View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

February 10, 2022

Study Completion Date

February 10, 2022

Conditions
Coronavirus Infection
Interventions
DRUG

INO-4800

INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.

DEVICE

CELLECTRA® 2000

EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

40509

Central Kentucky Research Associates, Lexington

64114

Center for Pharmaceutical Research, Kansas City

Sponsors
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Inovio Pharmaceuticals

INDUSTRY

NCT04336410 - Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | Biotech Hunter | Biotech Hunter